Clal Biotechnology Industries

Clal Biotechnology Industries 的所有者是 AAR Consortium. AAR Consortium 在 15 个国家有直接业务。

AAR Consortium 拥有 46家子公司，其中包括 A1、ABH Holdings 和 Access Industries。

他们在：

• 音乐30%
• 传媒11%
• 其他60%

查看带有其 12 名主要高管的组织结构图

Clal Biotechnology Industries 搜索最多的简介

• Assaf Segal, Acting Chief Executive Officer
• Nufar Malovani, Director
• Sigalia Heifetz, Director

创建提醒
跟踪 Clal Biotechnology Industries 的高管变动

AAR Consortium 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。

Popular M&A news in 生物技术

• Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
• Metsera 刚刚宣布为 500 筹款数百万美元。 (公布2024十一月20号).
• TRexBio 刚刚宣布为 84 筹款数百万美元。 (公布2024十一月14号).

生物技术 行业的其他推荐联系人

• Scholar Rock 企业 Kristina Burow - Director
• UroGen 企业 Fred Cohen - Director
• Adaptimmune Therapeutics 企业 Ali Behbahani - Non-Executive Director

了解更多有关生物技术行业的信息 >

Clal Biotechnology Industries 的最新新闻稿

• אסיפת בעלי מניות 31.10.2024 14:00 – CBI
• MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma | MediWound
• MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers | MediWound
• Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 – Investors – Gamida Cell Ltd.
• BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization | BioLineRx
• BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer | BioLineRx
• BioLineRx Announces Preliminary Phase 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients With Metastatic Pancreatic Cancer | BioLineRx
• BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer | BioLineRx
• BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition | BioLineRx
• Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in Non-Alcoholic Steatohepatitis (NASH)
• View more press releases Close

关于 Clal Biotechnology Industries 的社交媒体

• Clal Biotechnology Industries 在 维基百科、谷歌新闻 和 雅虎财经
• Clal Biotechnology Industries 在 LinkedIn、叽叽喳喳 和 YouTube

通过电子邮件联系联系该企业高管，包括 Avi Fischer

致电Clal Biotechnology Industries，电话：+972 ...

查看组织结构图

Register to receive your alert

报告错误